119 related articles for article (PubMed ID: 21281225)
1. JAK2V617F mutation is associated with special alleles in essential thrombocythemia.
Hsiao HH; Liu YC; Tsai HJ; Lee CP; Hsu JF; Lin SF
Leuk Lymphoma; 2011 Mar; 52(3):478-82. PubMed ID: 21281225
[TBL] [Abstract][Full Text] [Related]
2. Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations.
Okabe M; Yamaguchi H; Usuki K; Kobayashi Y; Kawata E; Kuroda J; Kimura S; Tajika K; Gomi S; Arima N; Mori S; Ito S; Koizumi M; Ito Y; Wakita S; Arai K; Kitano T; Kosaka F; Dan K; Inokuchi K
Leuk Res; 2016 Jan; 40():68-76. PubMed ID: 26614694
[TBL] [Abstract][Full Text] [Related]
3. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.
Senín A; Fernández-Rodríguez C; Bellosillo B; Camacho L; Longarón R; Angona A; Besses C; Álvarez-Larrán A
Ann Hematol; 2018 Mar; 97(3):443-451. PubMed ID: 29181548
[TBL] [Abstract][Full Text] [Related]
4. Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera.
Tiong IS; Casolari DA; Nguyen T; Van Velzen MJ; Ambler K; D'Andrea RJ; Ross DM
Blood Cancer J; 2016 Aug; 6(8):e459. PubMed ID: 27540717
[No Abstract] [Full Text] [Related]
5. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
[TBL] [Abstract][Full Text] [Related]
6. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
Kilpivaara O; Levine RL
Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026
[TBL] [Abstract][Full Text] [Related]
7. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.
Pardanani A; Lasho TL; Finke C; Mesa RA; Hogan WJ; Ketterling RP; Gilliland DG; Tefferi A
Stem Cells; 2007 Sep; 25(9):2358-62. PubMed ID: 17540852
[TBL] [Abstract][Full Text] [Related]
8. JAK2V617F allele burden in patients with myeloproliferative neoplasms.
Alshemmari SH; Rajaan R; Ameen R; Al-Drees MA; Almosailleakh MR
Ann Hematol; 2014 May; 93(5):791-6. PubMed ID: 24362471
[TBL] [Abstract][Full Text] [Related]
9. Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.
Yönal İ; Dağlar-Aday A; Akadam-Teker B; Yılmaz C; Nalçacı M; Yavuz AS; Sargın FD
Turk J Haematol; 2016 Jun; 33(2):94-101. PubMed ID: 25913509
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects between MPL and JAK2V617F on thrombosis and peripheral blood cell counts in patients with essential thrombocythemia: a meta-analysis.
Yang E; Wang M; Wang Z; Li Y; Wang X; Ming J; Xiao H; Quan R; Liu W; Hu X
Ann Hematol; 2021 Nov; 100(11):2699-2706. PubMed ID: 34383101
[TBL] [Abstract][Full Text] [Related]
11. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.
Kittur J; Knudson RA; Lasho TL; Finke CM; Gangat N; Wolanskyj AP; Li CY; Wu W; Ketterling RP; Pardanani A; Tefferi A
Cancer; 2007 Jun; 109(11):2279-84. PubMed ID: 17440984
[TBL] [Abstract][Full Text] [Related]
12. [Expression of JAK2V617F and MPLW515L/K mutation in 30 suspected cases of early myeloproliferative disorders].
Fan Z; Zhang R; Shen YM; Fei HR; Zhu ZL; Cen JN
Zhonghua Xue Ye Xue Za Zhi; 2008 Sep; 29(9):611-4. PubMed ID: 19175989
[TBL] [Abstract][Full Text] [Related]
13. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.
Hsiao HH; Yang MY; Liu YC; Lee CP; Yang WC; Liu TC; Chang CS; Lin SF
Exp Hematol; 2007 Nov; 35(11):1704-7. PubMed ID: 17920754
[TBL] [Abstract][Full Text] [Related]
14. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.
Lussana F; Carobbio A; Salmoiraghi S; Guglielmelli P; Vannucchi AM; Bottazzi B; Leone R; Mantovani A; Barbui T; Rambaldi A
J Hematol Oncol; 2017 Feb; 10(1):54. PubMed ID: 28228104
[TBL] [Abstract][Full Text] [Related]
15. Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms.
Hu L; Pu L; Ding Y; Li M; Cabanero M; Xie J; Zhou D; Yang D; Zhang C; Wang H; Zhai Z; Ru X; Li J; Xiong S
Hematology; 2017 Jul; 22(6):354-360. PubMed ID: 27976991
[TBL] [Abstract][Full Text] [Related]
16. A case of JAK2V617F-positive essential thrombocythemia where allele burden was reduced by a PD-1 inhibitor.
Hara R; Kawada H; Kikuti YY; Kikkawa E; Harada K; Aoyama Y; Ogiya D; Toyosaki M; Suzuki R; Machida S; Ohmachi K; Onizuka M; Ogawa Y; Masuda R; Iwazaki M; Nakamura N; Ando K
Int J Hematol; 2021 Apr; 113(4):606-610. PubMed ID: 33389657
[TBL] [Abstract][Full Text] [Related]
17. Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.
Guo H; Chen X; Tian R; Chang J; Li J; Tan Y; Xu Z; Ren F; Zhao J; Pan J; Zhang N; Wang X; He J; Yang W; Wang H
PLoS One; 2015; 10(9):e0138250. PubMed ID: 26375990
[TBL] [Abstract][Full Text] [Related]
18. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.
Pardanani AD; Levine RL; Lasho T; Pikman Y; Mesa RA; Wadleigh M; Steensma DP; Elliott MA; Wolanskyj AP; Hogan WJ; McClure RF; Litzow MR; Gilliland DG; Tefferi A
Blood; 2006 Nov; 108(10):3472-6. PubMed ID: 16868251
[TBL] [Abstract][Full Text] [Related]
19. The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis.
Qin Y; Wang X; Zhao C; Wang C; Yang Y
Int J Hematol; 2015 Aug; 102(2):170-80. PubMed ID: 25997869
[TBL] [Abstract][Full Text] [Related]
20. Investigation of T-cell immunoglobulin- and mucin-domain-containing molecule-3 (TIM-3) polymorphisms in essential thrombocythaemia (ET).
Han F; Wang G; Li Y; Tian W; Dong Z; Cheng S; Liu Y; Qu T; Wang X; Wang Y; Zhang B; Ju Y
Hematology; 2017 Jul; 22(6):361-367. PubMed ID: 27990849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]